Recce Pharmaceuticals Ltd (ASX:RCE) has been awarded over $17 million

Company News

by Rachael Jones

Recce Pharmaceuticals Ltd (ASX:RCE) has been awarded over $17 million of Synthetic Antibiotic Research & Development applicable expenditure by AusIndustry.

The Advanced Overseas Finding is a pillar of the R&D Tax Incentive Program administered by the Australian Government.

The Australian Government has further agreed to extend the R&D cash rebate to include the Company’s overseas R&D activites, for a period of three years (1 July 2019 to 30 June 2022).

With Recce’s anti-infective program predominantly focused on Synthetic Antibiotic Development, the Advanced Overseas Finding award will significantly extend the Company’s cash-runway on top of their recent $27.95 million capital raise, through non-diluative government funding.

Shares in Recce Pharmaceuticals Ltd (ASX:RCE) are trading flat at $1.13.
 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.